Low End $39.6M for Stem Cell Push
Hey Jalousie: IPO Window Still Open, but Pricing ‘Fates’ Vary
By Randy Osborne
Tuesday, October 1, 2013
The latest to price its initial public offering (IPO), Fate Therapeutics Inc. garnered about $39.6 million, an amount at the low end of its already-dipped target range, selling about 6.6 million shares at $6 each. Shares of San Diego-based Fate (NASDAQ:FATE) closed Tuesday at $6.62, up 10.3 percent.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.